After the thrombus formation in cardiac cavities or coronaries, the serine protease thrombin is produced and can therefore reach the myocardial tissue by the active process of extravasation and binds to the G protein-coupled protease-activated receptor-1 (PAR1) expressed in human myocardium. The role of PAR1 was investigated in the thrombin effect on sodium current (I Na ). I Na was recorded in freshly isolated human atrial myocytes by the whole-cell patch-clamp method. Action potentials (AP) were recorded in guinea pig ventricular tissue by the conventional glass microelectrode technique. Thrombinactivated PAR1 induced a tetrodotoxin-blocked persistent sodium current, I NaP , in a concentration-dependent manner with an apparent EC 50 of 28 U/ml. The PAR1 agonist peptide SFLLR-NH 2 (50 M) was able to mimic PAR1-thrombin action, whereas PAR1 antagonists N 3 -cyclopropyl-7-((4-(1-methylethyl)-phenyl)methyl)-7H-pyrrolo(3,2-f)quinazoline-1,3-diamine (SCH 203099; 10 M) and 1-(3,5-di-tert-butyl-4-hydroxy-phenyl)-2-[3-(3-ethyl-3-hydroxy-pentyl)-2-imino-2,3-dihydro-imidazol-1-yl]-ethanone (ER 112787) (1 M), completely inhibited it. The activated PAR1 involves the calcium-independent phospholipase-A 2 signaling pathway because two inhibitors of this cascade, bromoenol lactone (50 M) and haloenol lactone suicide substrate (50 M), block PAR1-thrombin-induced I NaP . As a consequence of I NaP activation, in guinea pig right ventricle papillary muscle, action potential duration (APD) were significantly increased by 20% and 15% under the respective action of 32 U/ml thrombin and 50 M SFLLR-NH 2 , and these increases in APD were prevented by 1 M tetrodotoxin or markedly reduced by application of 1 M SCH 203099 or ER 112787. Thrombin, through PAR1 activation, increases persistent component of the Na ϩ current resulting in an uncontrolled sodium influx into the cardiomyocyte, which can contribute to cellular injuries observed during cardiac ischemia.
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Thrombin is a serine protease released by thrombus with well-characterized roles in hemostasis, inflammation, and proliferative process. During cardiac ischemia reperfusion, thrombin is an important mediator of myocardial injury (Erlich et al., 2000) . Indeed, thrombin can permeate vessels or endocardial barrier by extravasation and therefore can affect the first layers of cardiomyocytes. Thus, thrombin levels may be locally elevated at site of vascular injury and thrombus formation and reach an activity as high as 10 to 30 U/ml (Park et al., 1994) . Then, thrombin has multiple cellular effects mediated by a family of G-protein-coupled proteaseactivated receptors (PARs), of which PAR1 is the prototype (Coughlin, 2000) . PAR1 are expressed in human myocardium (Jiang et al., 1996) and activates a spectrum of biochemical signals leading to changes in contractile performance and alteration in gene expression (Glembotski et al., 1993) , sarcomeric organization, and cardiomyocyte morphology (Sabri et al., 2002) . As shown recently, theses phenomenons are clearly involved in human coronary atherosclerosis and can lead to endothelial dysfunction and vascular inflammation (Lavi et al., 2007) . Thus, thrombin stimulates phosphoinositide hydrolysis, for instance by converting phosphatidylcho-line into lysophosphatidylcholine (LPC), via PLA 2 (Park et al., 1994; Sabri et al., 2000) . Thrombin also activates the extracellular signal-regulated protein kinase (Sabri et al., 2002) , facilitates rapid sodium current (Pinet et al., 2002) , modulates calcium homeostasis (Steinberg et al., 1991 (Steinberg et al., , 2005 , increases arrhythmias (Goldstein et al., 1994) , and hastens recovery from an imposed acid load by activating Na ϩ -H ϩ exchange (Avkiran and Haworth, 2003) . Taken together, these signal events profoundly alter electrophysiological properties and contractile behavior and could induce cardiomyocyte toxicity during the myocardial ischemiareperfusion injuries.
Increase in intracellular sodium during ischemia plays a key role in intracellular calcium overload, resulting in myocyte injuries. The involvement of thrombin-dependent activation of PAR1 in Na ϩ entry during ischemia has never been assessed. In a previous study, we reported that thrombin can reversibly act as direct agonist on I Na . The main consequences of this action were the shift toward hyperpolarizing potentials of the activation-voltage relationship, the large increase in peak I Na amplitude, and the consequent increase in the window of sodium current; however, this effect was independent of PAR1 activation (Pinet et al., 2002) . The present study examines whether PAR1 signaling in human cardiomyocytes is involved in the effect of thrombin on sodium current specially the persistent sodium current (I NaP ) (Haigney et al., 1994; Maltsev et al., 1998; Fedida et al., 2006; Noble and Noble, 2006; Saint, 2006) . The main result was that thrombin, by binding to PAR1 receptor, activates I NaP .
Materials and Methods
Heart Tissue Samples. Protocols for obtaining human cardiac tissue were in conformation with the principles outlined in the Declaration of Helsinki. We used a total of 62 specimens of human right atrial appendages that were obtained from hearts of patients (51-74 years old) undergoing heart surgery for coronary artery bypass graft or valve replacement. Seven percent of patients had received ␤-adrenergic receptor blockers, 38% had received calcium antagonists, 45% had received antiulcer drugs, 8% had received diuretics, and 22% had received antithrombotics. Treatments were usually stopped 24 h before operation. Patients with atrial dilation were avoided, and none had a history of supraventricular arrhythmias.
Cell Isolation. Human atrial myocytes were isolated enzymatically as described previously (Antoine et al., 1998) . The same chunk procedure was used to isolate myocytes from the right ventricle of guinea pig hearts, except that elastase was omitted in the chunks predigestion bath. Only quiescent rod-shaped myocytes with clear cross-striations, sharp edges, and a well delineated cell membrane were chosen for experiments. Small myocytes were preferred to optimize spatial voltage-clamp.
Solutions and Drugs. For whole-cell current recordings, the intracellular pipette solution contained 5 mM NaCl, 130 mM CsCl, 2 mM MgCl 2 , 1 mM CaCl 2 , 15 mM EGTA, 10 mM HEPES, and 4 mM MgATP, pH adjusted to 7.2 with CsOH; the basal external solution contained 25 mM NaCl, 108.5 mM CsCl, 2.5 mM CoCl 2 , 0.5 mM CaCl 2 , 2.5 mM MgCl 2 , 5 mM 4-aminopyridine, 10 mM HEPES, and 10 mM glucose, pH adjusted to 7.4 with CsOH. Hirudin (from leeches, Ϸ2000 U/mg) was from Roche (Mannheim, Germany). Haloenol lactone suicide substrate (HELSS) from TEBU France, was dissolved in dimethyl sulfoxide that did not exceed 0.05%. The PAR1 agonist (SFLLR-NH 2 ) and antagonist SCH 203099 were from the Division of Medicinal Chemistry IV (Centre de Recherche Pierre Fabre, Castres, France), ␣-thrombin (human plasma Ϸ 1000 U/mg), and other chemicals were purchased from Sigma (St. Quentin Fallavier, France). Commercially available lyophilized thrombin is provided as a sodium salt. The addition of 32 U/ml thrombin to the basal perfusion medium containing 25 mM NaCl increases the Na ϩ activity to 32.1 Ϯ 0.3 mM (n ϭ 10) (measured with a sodium ion-selective electrode). The control perfusion medium was therefore supplied with NaCl to keep the Na ϩ activity equivalent. Current Recordings. Ionic currents were recorded by the wholecell patch-clamp technique with a patch-clamp amplifier (Axopatch 200B, Axon Instruments, Foster City, CA). Patch pipettes (Corning Kovar Sealing code 7052; World Precision Instruments, Sarasota, FL) had resistances of 0.5 to 2.0 M⍀. Currents were filtered at 20 kHz (Ϫ3 dB, eight-pole, low-pass Bessel filter) and digitized at 50 kHz (Digidata 1200; Molecular Devices, Sunnyvale, CA).
Cell membrane capacitance was 48.2 Ϯ 2.6 pF (n ϭ 67 cells, from 62 donors) for human atrial myocytes and 62.4 Ϯ 7.5 pA/pF (n ϭ 18, from 10 hearts) for guinea pig right ventricular myocytes. Series resistance was compensated at 80 to 95%, resulting in voltage errors of Ͻ3 mV. Leakage current was compensated for, whereas cell membrane capacitive current was not. Peak I Na and I NaP amplitudes were monitored according to a steady-state pulse protocol: a 1000-ms depolarizing test pulse to Ϫ30 mV from a HP of Ϫ100 mV at 0.2 Hz. It is noteworthy that the test pulse chosen was beyond the upper limit of the potential range inside which the sodium window current has been observed to increase under the direct effect of thrombin on sodium channel (Pinet et al., 2002) . To avoid a putative overlap between PAR1-induced I NaP and thrombin-increased sodium window current, experiments were also performed with test pulse to Ϫ10 mV. An equilibration period was allowed until peak I Na reached steady state and remained stable without evidence of a leftward shift of the availability-voltage relationship (h ϱ -V m ). This protocol was designed to detect any such shifts. After each sequence of five depolarizing pulses, HP was set to Ϫ140 mV. Consequently, during the stabilization period, when peak current amplitude was higher after a HP at Ϫ140 mV compared with Ϫ100 mV, the recording was discarded. Likewise, because thrombin has no effect on the h ϱ -V m relationship (Pinet et al., 2002) , recordings showing an irreversible hyperpolarizing shift of h ϱ -V m after thrombin application were also discarded. The steady-state pulse protocol was applied in control, thrombin, or when other substances were tested and washed out. Experiments were carried out at room temperature (22-25°C).
Action Potential Recording. Male guinea pigs were anesthetized by intraperitoneal pentobarbital sodium injection, and their hearts were quickly removed. The investigation conforms with the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health (NIH Publication no. 85-23, revised 1996) . A total of 21 hearts were used for the AP study. Papillary muscles were dissected from the right ventricle and superfused (4-6 ml/min) with the Krebs' solution maintained at 36.0 Ϯ 0.5°C in a 5-ml tissue bath. The Krebs' solution was oxygenated with 95% O 2 /5% CO 2 and had the following composition: 113.1 mM NaCl, 4.6 mM KCl, 2.45 mM MgCl 2 , 3.5 mM NaH 2 PO 4 , 21.9 mM NaHCO 3 , and 5 mM glucose, pH 7.4. Action potentials (AP) were recorded by conventional "floating" glass microelectrodes (5-20 M⍀) filled with 3 M KCl and were coupled to a high-input impedance preamplifier (VF 102; Biologic, Echirolles, France). The preparations were electrically stimulated (Pulsar BP; FHC, Bowdoin, ME) with 1-ms pulses at 1.5 times the threshold voltage through a bipolar Ag-electrode. APs were displayed on a dual-beam oscilloscope (TDS 2012; Tektronics, Heerenveen, The Netherlands) and simultaneously digitized and analyzed with interactive software (NOTOCORD-hem 3.4; Notocord Systems, Croissy Sur Seine, France). The preparations were allowed to equilibrate for at least 1 h at a stimulation rate of 1 Hz. A single impalement was maintained throughout control and compound superfusion periods. AP parameters measured were maximum upstroke velocity [(dV/dt) max ], amplitude, resting membrane potential, and action potential duration (APD) at 50 and 90% repolarization levels (APD 50 and APD 90 , respectively). Data Analysis and Statistics. As much as possible, depending on the experimental protocol performed, only the TTX-inhibited PAR1-induced I NaP was taken into account and determined by sub-PAR-1 and PLA 2 Cascade Mediate Thrombin-Induced I NaP tracting the current obtained under concomitant application of TTX and thrombin or SFLLR-NH 2 from that previously recorded under thrombin alone. The amplitude of TTX-blocked thrombin-induced I NaP was the mean current calculated from 80 to 180 ms after the beginning of the depolarization (Valdivia et al., 2002) . Peak I Na amplitude was measured with respect to current amplitude at the end of the test pulse. Data are expressed as means Ϯ S.E.M. of n determinations or myocytes. Statistical analysis were performed by using paired or unpaired Student's t test or analysis of variance, as appropriate, and the null hypothesis was rejected at the 0.05 level; ‫,ء‬ p Ͻ 0.05; ‫,ءء‬ p Ͻ 0.01; and ‫,ءءء‬ p Ͻ 0.001.
Results
Thrombin Application Induced a Persistent Sodium Current Different from the Thrombin-Increased Sodium Window Current. To be beyond the upper limit of the range of membrane potential (from Ϫ85 to Ϫ40 mV) in which sodium window current occurs, a test pulse to Ϫ30 mV was used to elicit I Na (Pinet et al., 2002) . Local perfusion of 32 U/ml thrombin on freshly isolated human atrial myocytes caused the already described marked increase in peak of I Na ( Fig. 1 A) , which occurred rapidly ( Fig. 1D ) and was shown to be completely independent of the activation of PAR1 receptors (Pinet et al., 2002) . In addition to this effect on peak I Na , after a longer time of application, over 6 min, thrombin induced very slowly inactivating or persistent TTX-blocked sodium current (Fig. 1, B and D) , termed I NaP . Although the increase in peak I Na was observed in all tested cells, the induction of I NaP was observed in 51 of 67 cells, most proba- Fig. 1 . Rapid sodium current was modified after thrombin application to human atrial myocytes. A shows that thrombin (32 U/ml) was able to increase the TTX-blocked fast sodium current I Na , as described previously. In B, the vertical scale shows a higher gain than in A, and the time base is slowed to demonstrate the effect of thrombin on the noninactivating persistent component of the current (I NaP ), which was blocked by 50 M TTX. Arrows indicate zero current level. C, concentration-response curve for thrombin-induced I NaP . Normalized mean increase in I NaP amplitude is reported against thrombin activity. Each point represents the mean Ϯ S.E.M. of n measurements indicated. Data points were fitted by the equation Y/Y max ϭ 1/[1 ϩ (EC 50 /thrombin activity) nH ]. Y max (maximum mean induced-I NaP ), EC 50 (activity inducing half-maximal effect), and Hill parameter n H were, 3.98 pA/pF, 28.4 U/ml, and 1.98 for I NaP , respectively. D, kinetic of the effect of thrombin on I NaP and on peak I Na . Time courses of I NaP (top) and of peak I Na (middle) densities, and percentage of induced I NaP over peak I Na (bottom), under conditions indicated by horizontal bars. Currents were elicited by depolarization from HP ϭ Ϫ140 to Ϫ30 mV. E, bar graphs correspond to the time necessary to obtain the thrombin maximal effect on the two currents; the number of measurements is in parentheses.
bly as a consequence of the lost and/or damage caused to PAR1 receptors by the enzymatic procedure used for cell dissociation. Thrombin (32 U/ml) increased peak I Na from Ϫ118.9 Ϯ 12.6 to Ϫ191.7 Ϯ 20.8 pA/pF (n ϭ 23; p Ͻ 0.001, paired t test) and induced I NaP in a concentration-dependent manner (Fig. 1C) . At this concentration of thrombin, maximum increase in I NaP was 1.8% of control peak I Na . The density of I NaP was Ϫ0.02 Ϯ 0.01 pA/pF, n ϭ 3, with 1 U/ml thrombin, Ϫ0.50 Ϯ 0.02 pA/pF, n ϭ 3, with 10 U/ml thrombin, Ϫ2.23 Ϯ 0.54 pA/pF, n ϭ 6, with 32 U/ml thrombin, and Ϫ3.69 Ϯ 0.82 pA/pF, n ϭ 4, with 100 U/ml thrombin. Estimated-maximal density of I NaP was Ϫ3.98 pA/pF, and the apparent EC 50 and the Hill coefficient were 28.4 U/ml and 1.98, respectively. This concentration-response relationship exhibits clear differences compared with the reported concentration-response of the effect on peak I Na (Pinet et al., 2002) where EC 50 and Hill coefficient were 91 U/ml and 0.75, respectively. Thrombin-induced I NaP was not a residual current resulting from the thrombin-enhanced window sodium current (Pinet et al., 2002) , because the increase in I NaP , with 32 U/ml thrombin, was observed with test pulses to Ϫ10 mV, a membrane potential at which the window current could not be activated (I NaP density was Ϫ1.71 Ϯ 0.83 pA/pF; n ϭ 5). These two distinct effects of thrombin on sodium current (increase in peak I Na and in I NaP ) were suppressed by 50 M TTX, a specific sodium channel blocker (Fig. 1, A and B) . It is noteworthy that the difference in kinetics of thrombin effect on peak I Na compared with the onset of I NaP (Fig. 1D) and that the time to reach maximum thrombin effects was much longer for I NaP (416.0 Ϯ 40.4 s, n ϭ 15) than for peak I Na (61.7 Ϯ 10.1 s, n ϭ 12; Fig. 1E ), suggesting distinct underlying mechanisms. This is also supported by the observation that after washout of thrombin, the amplitude of peak I Na returned to the basal (Pinet et al., 2002) but not that of I NaP (Fig. 1D ), in accordance with the irreversibility of the cleavage of PAR1 by thrombin. The below of Fig. 1D exemplifies the prominence of thrombin effect on I NaP over the effect on peak I Na , when the latter effect wore out.
Involvement of the PAR1 in Thrombin-Induced I NaP . To test further for the requirement of protease activity of thrombin in the activation of I NaP , we investigated the effect of hirudin, a direct protease inhibitor of thrombin. The induction of I NaP by 32 U/ml thrombin was markedly reduced in presence of 320 U/ml hirudin (Fig. 2B-D) ; I NaP density was, under thrombin, Ϫ2.27 Ϯ 0.51 pA/pF (n ϭ 8) versus Ϫ0.43 Ϯ 0.19 pA/pF under thrombin in presence of hirudin (n ϭ 9; p Ͻ 0.001), whereas the effect of thrombin on peak I Na was unchanged (Fig.  2, A and C) . This result confirms that the protease activity of thrombin was necessary to activate I NaP , probably through the cleavage of still undefined target proteins. Among the proteins cleaved by thrombin, the most likely target protein is the well known PAR1 receptor. To study the involvement of this receptor, the selective PAR1-antagonist SCH 203099 (Ahn and Chackalamannil, 2001 ) has been used. After human atrial cell preincubation with 10 M SCH 203099 for at least 15 min, thrombin failed to induce I NaP [ Fig. 3 , B-D; Ϫ0.30 Ϯ 0.07 pA/pF (n ϭ 14) versus Ϫ2.27 Ϯ 0.51 pA/pF, n ϭ 8 in absence of SCH 203099 (p Ͻ 0.001)], whereas the thrombin effect on peak I Na was unaffected [ Fig. 3 , A and C; from Ϫ103.7 Ϯ 14.1 pA/pF under SCH 203099 to Ϫ158.4 Ϯ 21.6 pA/pF (n ϭ 14) after addition of 32 U/ml thrombin (p Ͻ 0.001)]. These results suggest that PAR1 activation constitutes a key mechanism for the thrombin-induced I NaP . Then, the ability of the PAR1 agonist peptide SFLLR-NH 2 to putatively mimic the role of thrombin in induction of I NaP via PAR1 was tested (Fig. 4) . SFLLR-NH 2 stimulated I NaP [mean increased: Ϫ1.46 Ϯ 0.63 pA/pF, n ϭ 5, p Ͻ 0.05 versus control (Fig. 4, B and C) ], exhibiting a fair reversibility upon washout (Fig. 4 , B and D) but failed to increase peak I Na (Fig. 4, A and D) . Taken together, the present results demonstrate that the thrombin-induced I NaP is mediated by PAR1 activation. Fig. 2 . The effect of hirudin, a direct inhibitor of the protease activity of thrombin, was tested on thrombin-induced I NaP . Typical current recordings (represented as in Fig. 1) showing that coapplication of hirudin (320 mM) left unchanged the increase in peak I Na by thrombin (32 U/ml) (A) but prevents the thrombin-induced I NaP (B). C, kinetic comparisons of the action of thrombin in presence of hirudin on I NaP and on peak I Na . Time courses of I NaP (upper trace) and of peak I Na (lower trace) densities, under conditions indicated by horizontal bars. Currents were elicited as described in the legend to Fig. 1 . D, bar graphs confirm that hirudin prevented the induction of I NaP by thrombin.
PAR-1 and PLA 2 Cascade Mediate Thrombin-Induced I NaP 1625
at ASPET Journals on April 2, 2017 molpharm.aspetjournals.org
Downloaded from
Involvement of Ca 2؉ -Independent Phospholipase-A 2 Pathways after PAR1 Activation. PAR1 is a member of the G-protein-coupled receptor family; therefore, its activation stimulates numerous intracellular signaling pathways (Coughlin, 2000) . Several studies have reported that in cardiomyocytes, thrombin stimulates the Ca 2ϩ -independent phospholipase A 2 (PLA 2 ) via PAR1, which produced an intracellular lysophosphatidyl choline (LPC) accumulation (Park et al., 1994; Yan et al., 1995) . Therefore, two inhibitors of PLA 2 [bromoenol lactone (BEL) and haloenol lactone suicide substrate (HELSS)] were used to investigate whether PLA 2 activity is involved in the enhancement of I NaP , induced by PAR1 stimulation. After cell incubation with BEL for at least 30 min, thrombin had its usual effect on peak I Na (Fig. 5A ) but failed to stimulate I NaP (Fig. 5B,  Ϫ0 .22 Ϯ 0.11 pA/pF, n ϭ 5 versus Ϫ2.27 Ϯ 0.51 pA/pF, n ϭ 8, in the absence of BEL; p Ͻ 0.01). A similar result was obtained with HELSS (Fig. 5C ). The density of I NaP activated in presence of thrombin and HELSS was Ϫ0.39 Ϯ 0.14 pA/pF, n ϭ 5 (p Ͻ 0.01). These results indicate that the PAR1-induced I NaP required the activation of Ca 2ϩ -independent PLA 2 . Fig. 3 . Because the induction of I NaP depended on the protease activity of thrombin, the involvement of the protease-activated-receptor 1 (PAR1) was tested using the PAR1 antagonist SCH 203099. A, current traces showing that SCH 203099 does not prevent the increase in peak I Na by thrombin, whereas it blocks the thrombin-induced I NaP (B). C, time courses of I NaP and I Na densities, under conditions indicated by horizontal bars. D, bar graphs summarize the effect of SCH 203099 versus thrombin on I NaP . Thrombin was used at 32 U/ml and SCH 203099 at 10 M. Fig. 4 . SFLLR-NH 2 , a synthetic PAR1 agonist peptide, was able to reproduce the potent induction of I NaP by thrombin but not the increase in peak I Na . Typical current traces of I Na (A) showing activation of I NaP and that peak I Na remained unchanged under SFLLR-NH 2 . B, the corresponding traces with different amplitudeand time-scales on right hand. C and D, the effect of SFLLR-NH 2 on I Na was compared with thrombin-activation of I NaP . In C, typical traces of I NaP were obtained under control, SFLLR-NH 2 and thrombin conditions. In D, comparison of I NaP (top) and I Na (middle) time courses, and percentage of I NaP over I Na (bottom), under conditions indicated by horizontal bars, showing the activation of I NaP by SFLLR-NH 2 , followed by its partial reversion upon washout, and the usual effects of thrombin. SFLLR-NH 2 was used at 50 M and thrombin at 32 U/ml.
Thrombin and PAR1 Agonist Peptide SFLLR-NH 2
Increased Action Potential Duration. To examine the consequence of activation of I NaP by thrombin and PAR1 agonist peptide SFLLR-NH 2 on cardiac tissue electrical activity, we recorded action potentials in right ventricle papillary muscle from guinea pigs. We used the classic microelectrode technique, which allows a stable and reliable AP recording during prolonged period as required for the study of the delayed effect of thrombin on I NaP . We first checked that, in this species and in ventricular cells, thrombin also activates I NaP by performing patch-clamp experiments in isolated guinea pig ventricular myocytes. Test pulses to Ϫ10 mV from a holding potential of Ϫ80 mV were used to elicit current. Immediate application of thrombin (32 U/ml) increased peak I Na (Fig. 6A, a and b ) from Ϫ112.6 Ϯ 11.5 to Ϫ166.9 Ϯ 16.4 pA/pF, n ϭ 11 (p Ͻ 0.001; paired t test), blocked by application of 50 M TTX. Moreover, after 7 min of application, thrombin induced a TTX-sensitive I NaP of Ϫ2.91 Ϯ 1.1 pA/pF, n ϭ 9 (Fig. 6A, b and d) . The increase in I NaP was 0.026% of control peak I Na . This effect was blocked by the PAR1 antagonist ER 112787 (Barry et al., 2006; Chackalamannil and Xia, 2006) (Fig. 6B) . After myocytepreincubation with 1 M ER 112787 for at least 5 min, thrombin did not induced I NaP [Fig. 6B, b, c, and d; Ϫ0 .076 Ϯ 0.05 pA/pF (n ϭ 5) versus Ϫ2.91 Ϯ 0.68 pA/pF, in absence of drug, n ϭ 9; p Ͻ 0.001], whereas the effect of thrombin on peak I Na was unaffected (Fig. 6A, a and c; Ϫ87.3 Ϯ 6.1 pA/pF, n ϭ 5, under ER 112787 to Ϫ123.4 Ϯ 10.3 pA/pF, n ϭ 9, after addition of thrombin; p Ͻ 0.05). Figure 7A , a, shows the effects of thrombin (32 U/ml) and SFLLR-NH 2 on action potentials recorded from right papillary ventricle. After a 10-min application, thrombin and SFLLR-NH 2 significantly increased APD measured at 50 and 90% of repolarization ( Fig. 7A and Table 1 ). At these two levels of repolarization, the increases in APD were 15.3 and 12.9%, respectively, for thrombin and 12.4 and 12.1% for SFLLR-NH 2 (Table 1 ). The increases in APD were barely reversible (Table 1) . It is noteworthy that in presence of TTX (1 M), applications of thrombin (32 U/ml) or SFLLR-NH 2 (100 M) failed to increase the action potential duration (Fig.  7A , b, and Table 2 ). We used a low concentration of TTX to minimize the consequences of the inhibition of peak I Na on AP upstroke.
To investigate the involvement of PAR1 on thrombin-and SFLLR-NH 2 -induced APD lengthening, two selective PAR1 antagonists, SCH 203099 and ER 112787, were then evaluated. Figure 7B , a and b, show that both SCH 203099 and ER 112787, in a concentration-dependent manner, reduced the thrombin-and SFLLR-NH 2 -induced APD prolongations. Thus, SCH 203099 (10 M) and ER 112787 (1 M) both fully blocked the APD prolongation induced by 100 M SFLLR-NH 2 (Fig. 7B) , a result that was in complete agreement with the potency of this antagonist against PAR1 (Chackalamannil and Xia, 2006) . Taken together, these results indicated that stimulation of the inward persistent Na ϩ current by protease-activated receptors after PAR1 activation can modify the AP duration.
Discussion
The present results demonstrate for the first time that thrombin induces a PAR1-mediated persistent sodium current component, I NaP , in cardiomyocytes. Because thrombin is a serine protease formed at the site of coronary vascular wall injury, this effect on Na current might have important consequences in the setting of myocardial ischemia.
Involvement of PAR1 Signaling Pathway in the Thrombin Effect on I NaP . The conclusion that thrombin enhances I NaP through the proteolytic cleavage of PAR1 is supported by the findings that this thrombin effect on current is mimicked by the PAR1 agonist peptide SFLLR-NH 2 and is fully blocked by the PAR1 antagonists, SCH 203099 and ER 112787 (Ahn and Chackalamannil, 2001) . Cleavage of the amino-terminal PAR1 exodomain unmasks a tethered Fig. 5 . Thrombin-induced I NaP requires activation of Ca 2ϩ -independent phospholipase A 2 . Effects of BEL, a PLA 2 inhibitor, upon thrombinincreased peak I Na (A) and thrombin-induced I NaP (B). A, sample current traces showing no effect of BEL on thrombin-increased peak I Na . B, the corresponding traces with different amplitude-and time-scales demonstrating that the presence of BEL prevented the induction of I NaP . Cell was previously preincubated with 50 M BEL for 30 min. C, bar graphs summarizing the inhibition of thrombin-induced I NaP after BEL incubation and HELSS application. Thrombin was used at 32 U/ml and HELSS at 10 M.
PAR-1 and PLA 2 Cascade Mediate Thrombin-Induced I NaP 1627 at ASPET Journals on April 2, 2017 molpharm.aspetjournals.org ligand that binds the receptor body to trigger intracellular signaling. Consequently, PAR1 is irreversibly activated by this proteolytic cleavage, contributing to keep on its signaltransducing capability. This could explain the low reversibility of the thrombin effect on I NaP upon washout (see Fig. 1 ). This was not the case for SFLLR-NH 2 (see Fig. 4 ), an exog- Fig. 6 . Guinea pig ventricular myocytes also exhibited a thrombin-increased I Na and a thrombin-induced I NaP . A, a, shows that thrombin (32 U/ml) was able to increase the TTXblocked fast sodium current I Na . b, the corresponding traces with different amplitude-and time-scales showing the TTX-blocked, thrombin-induced-I NaP recorded after 7-min application of thrombin (32 U/ml). TTX was used at 50 M. c and d, bar graphs summarizing the effects of thrombin and TTX on I Na and I NaP . B, with this cell type, another PAR1-antagonist, ER 112787, has been tested. a, current traces showing that ER 112787 did not prevent the increase in peak I Na by thrombin, whereas it blocked the thrombin-induced I NaP (b). c, time courses of I NaP and I Na densities, under conditions indicated by horizontal bars. d, bar graphs summarize the effect of ER 112787 versus thrombin on I NaP . Thrombin was used at 32 U/ml and ER 112787 at 1 M.
enous peptide that does not cleave the PAR1 and that exhibited an effect more sensitive to washout. Another evidence that thrombin effect on I NaP is mediated by PAR1 signaling pathways is provided by the observation that this effect is suppressed by the inhibition of PLA 2 by BEL and HELSS. There are previous studies showing that the increase in intracellular LPC levels plays an important role in the thrombin effect (Undrovinas et al., 1992; Park et al., 1994; Yan et al., 1995) . For instance, the cleavage of PAR1 by thrombin stimulates the amphipathic lipids catabolism leading to an accumulation of LPC in the intracellular medium (Undrovinas et al., 1992; Park et al., 1994 ). However, the precise level of the signaling pathway at which PLA 2 inhibitors were able to inhibit thrombin-induced I NaP remains to be clarified.
Nature of the I NaP Current. The intracellular accumulation of LPC could mediate the effect of thrombin on I NaP . The LPC is well known to maintain sodium channel in burst- ing activity, thus giving rise to noninactivating sodium current (Undrovinas et al., 1992) . The exact nature of this noninactivating sodium current is not yet fully elucidated. There is evidence that this persistent component of sodium current, I NaP , could be generated by a small fraction of the "normal" transient-mode sodium channel population, that undergoes burst or/and late scattered mode(s). Such modes have been recently described by Maltsev and Undrovinas (2006) for the persistent Na ϩ current in human ventricular myocytes. Thus, thrombin could favor this bursting activity of voltagegated sodium channels, by cleaving PAR1 and stimulating the conversion of phosphatidylcholine into LPC, which, via PLA 2 (Park et al., 1994; Sabri et al., 2000) , increases intracellular LPC (Undrovinas et al., 1992; Park et al., 1994) . In a previous study, we reported that thrombin stimulates the peak I Na and the sodium-window current. However, this effect, which is fast and fully reversible, is not mediated by PAR1 (Pinet et al., 2002) as further demonstrated in the present study. Moreover, thrombin was able to induce I NaP at membrane potentials as high as Ϫ10 mV, which is clearly not in membrane potential range of window current (from Ϫ85 to Ϫ40 mV). Finally, there are clear differences between the concentration-response curves of the effect of thrombin on peak I Na (Pinet et al., 2002) and on I NaP . One hypothesis currently tested concerning the direct effect of thrombin on peak I Na is the involvement of a ␤-subunit (Herfst et al., 2003) . The majority of Na ϩ channels in the heart correspond to the expression of the TTX-resistant Na V 1.5 isoform, and this is the case for human atrial myocytes (Makielski et al., 2003) . However, it cannot be excluded that thrombin-PAR1 activation targets another population of sodium channels (Brette and Orchard, 2006) . The effect of thrombin on I NaP that develops slowly is likely to have more significant consequences on cardiac myocyte.
Pathophysiological Consequences of the Activation by Thrombin of I NaP . Both persistent and window sodium current are known to participate to action potential duration. Although the window sodium current, which activates in a restricted membrane potential range from Ϫ85 to Ϫ40 mV, is involved in the late phase of repolarization and in the control of resting membrane potential (Pinet et al., 2002) , I NaP , activated from Ϫ10 mV, is found to contribute to the regulation of the early phase of APD (Kiyosue and Arita, 1989; Maltsev et al., 1998; Sakmann et al., 2000; Fedida et al., 2006; Noble and Noble, 2006; Wu et al., 2006) . It has been previously reported that blocking the I NaP with TTX caused a 10 to 20% decrease of APD, although this current is of very small density in control condition (Kiyosue and Arita, 1989; Maltsev et al., 1998; Sakmann et al., 2000) . Therefore, the progressive several-fold increase in I NaP by thrombin is likely to have a significant effect on APD, whereas, despite a fast increase in peak I Na (Fig. 1) , thrombin is devoid of significant effect on (dV/dt) max . Indeed, thrombin and SFLLR markedly increased the duration of action potentials of guinea pig papillary muscle. This effect of thrombin or SFLLR-NH 2 on AP duration can be largely explained by an increase of I NaP , because it was abolished by TTX. However, it cannot be excluded that the thrombin/PAR1 pathway can affect other ionic currents indirectly via changes in [Na] i and [Ca] i . Previous studies have shown that thrombin lengthens APD and increases cesium-induced early afterdepolarizations and pro-arrhythmic events in canine Purkinje fibers (Steinberg et al., 1991) and in intact adult rat hearts during early reperfusion (Jacobsen et al., 1996; Woodcock et al., 1998) . It has been shown also that suppression of the late sodium current can suppress EADs of myocytes isolated from failing hearts (Maltsev et al., 1998; Undrovinas et al., 2002; Valdivia et al., 2005; Fedida et al., 2006) . Thus, blocking I NaP by inhibiting PAR1 Ϫ PLA 2 pathway may be a new pharmacological target to reduce thrombin-induced arrhythmic activity. Yan et al. (1995) have demonstrated that activation of PAR1 by SFLLR-NH 2 peptide induced a rapid and dramatic elevation in [Na ϩ ] i , which was associated with a concomitant increase in LPC content in isolated, blood-perfused rabbit hearts in response to ischemia (Lavi et al., 2007) . The increase in [Na ϩ ] i could contribute to myocyte injury during ischemia as the result of intracellular calcium overload and the activation of Ca 2ϩ -dependent signaling cascades. This hypothesis is supported by the recent finding of the cardioprotective effects of the late sodium current inhibitor ranolazine . Moreover, in in vivo and in vitro studies, Strande et al. (2007) have shown that a preventive and a curative treatments with a selective PAR1 antagonist reduced the infarct size and increased ventricular function recovery after ischemia reperfusion in an isolated heart model. It remains to determine whether the increase in [Na ϩ ] i induced by SFLLR-NH 2 or by thrombin during ischemia is mediated by the activation of I NaP .
In conclusion, this study describes a new regulatory mechanism of sodium current involving PAR1-PLA 2 signaling pathway, which could be evoked by thrombin during cardiac ischemia and thrombus formation (Haigney et al., 1994; Maltsev et al., 1998) . Selective antagonists of PAR1 receptor, which are very efficient to suppress this effect of thrombin, might represent a novel cardioprotective strategy in the clinical setting of myocardial ischemia and reperfusion (Strande et al., 2007) .
